Importance and Presence of High-Quality Evidence for Clinical Decisions in Neurosurgery: International Survey of Neurosurgeons

Jill Martens*, BSc; Guido de Jong*, MSc; Maroeska Rovers*, PhD; Gert Westert*, PhD; Ronald Bartels*, MD, PhD
Neurosurgical Center Nijmegen, Department of Neurosurgery, Radboud University Medical Center, Nijmegen, Netherlands
* all authors contributed equally

Corresponding Author:
Jill Martens, BSc
Neurosurgical Center Nijmegen
Department of Neurosurgery
Radboud University Medical Center
Department of Neurosurgery, huispost 636
Postbus 9101
Nijmegen, 6500 HB
Netherlands
Phone: 31 681557132
Fax: 31 243635117
Email: jill.martens@radboudumc.nl

Abstract

Background: The publication rate of neurosurgical guidelines has increased tremendously over the past decade; however, only a small proportion of clinical decisions appear to be based on high-quality evidence.

Objective: The aim was to evaluate the evidence available within neurosurgery and its value within clinical practice according to neurosurgeons.

Methods: A Web-based survey was sent to 2552 neurosurgeons, who were members of the European Association of Neurosurgical Societies.

Results: The response rate to the survey was 6.78% (173/2552). According to 48.6% (84/173) of the respondents, neurosurgery clinical practices are based on less evidence than other medical specialties and not enough high-quality evidence is available; however, 84.4% (146/173) of the respondents believed neurosurgery is amenable to evidence. Of the respondents, 59.0% (102/173) considered the neurosurgical guidelines in their hospital to be based on high-quality evidence, most of whom considered their own treatments to be based on high-quality (level I and/or level II) data (84.3%, 86/102; significantly more than for the neurosurgeons who did not consider the hospital guidelines to be based on high-quality evidence: 55%, 12/22; \( P < .001 \)). Also, more neurosurgeons with formal training believed they could understand, criticize, and interpret statistical outcomes presented in journals than those without formal training (93%, 56/60 and 68%, 57/84 respectively; \( P < .001 \)).

Conclusions: According to the respondents, neurosurgery is based on high-quality evidence less often than other medical specialties. The results of the survey indicate that formal training in evidence-based medicine would enable neurosurgeons to better understand, criticize, and interpret statistical outcomes presented in journals.

KEYWORDS
evidence-based medicine; neurosurgery; levels of evidence

Introduction

Evidence-based neurosurgery is a paradigm of neurosurgical practice in which the best available evidence is consulted to establish the principles of diagnosis and treatment. These principles are applied considering the neurosurgeon’s training and experience, as well as being informed by the patient’s individual circumstances and preferences, to produce the best possible health outcomes [1]. Although evidence-based medicine (EBM) is the gold standard in medicine [1-3], it is estimated that only 10% to 25% of clinical decisions are based on high-quality evidence [4], defined as level I and level II evidence (see Table 1 for definitions) [5].
In 2011, a new rating system, the Grading of Recommendations Assessment, Development, and Evaluation (GRADE), was developed, which offers an outcome-centric system for rating the quality of evidence derived from different types of studies [6]. The GRADE guidelines enable the rating of the quality of evidence in systematic reviews and clinical guidelines, as well as a determination of the strength of recommendations made in these documents. To the best of our knowledge, neurosurgery is currently still using the levels of evidence more often than the GRADE guidelines.

Rothoerl et al [7] and Yarascavitch et al [5] published investigations into the levels of evidence in the neurosurgical literature in 2003 and 2012, respectively. These studies assigned a level of evidence to all published clinical papers in three major neurosurgical journals for the years 1999 and 2009-2010, respectively, graded according to the study design shown in Table 1 [5,8,9]. The authors found that 22.8% and 10.3% of evidence was considered higher-level evidence (level I or level II). Level I evidence, from randomized controlled trials yielding homogeneous results, was only found in 3.8% and 2.1% of the papers evaluated in these two studies, respectively.

These studies suggest that surgeons are increasingly turning their backs on research. Further evidence indicates that compared with a decade or two ago, surgeons apply for and receive fewer grants, publish less, and—perhaps most perniciously—feel that research is not part of their role [10]. Involvement in research allows surgeons to develop rigor in their everyday work and to judge, maintain, and improve the quality of the work done by their peers.

The goal of this study is to investigate the opinion of neurosurgeons about the evidence available in neurosurgical practice and the extent to which this evidence is implemented in clinical practice.

Methods

Recruitment

Evaluation by an ethical committee was not necessary for this study. A survey was conducted among 2552 members of the European Association of Neurosurgical Societies (EANS). The survey asked the opinion of neurosurgeons regarding the levels of evidence generated in neurosurgical studies, their understanding of the levels of evidence, and to what extent neurosurgeons implement evidence in clinical practice. The survey was emailed directly to the members of the EANS by the society’s administrative personnel. Data were collected over a period of 3 weeks from the date of the first mailing. Two reminders, each 1 week apart, were sent to the cohort.

Survey

The survey (Multimedia Appendix 1) was made using a Google Inc program (Google Forms) and consisted of 13 sections containing a total of 22 questions. Sections with multiple questions within the survey were randomized to minimize the influence of the sequence of questions on the answers. Levels of evidence were used instead of ratings determined using the GRADE recommendations because the levels are still more commonly used by neurosurgeons to the best of our knowledge. Participants were asked for their opinions on high-quality evidence, the usability of the results of different research methods in clinical practice, the amenability of neurosurgery to evidence, the quality of guidelines in their hospital and of the guidelines used by the neurosurgeons themselves, and the most important factors for choosing between treatments. The guidelines mentioned in the questionnaire were selected in a previous study [11], in which a PubMed search was used to identify the most recent guidelines available. These guidelines were then characterized by the strength of their evidence [11]. This search covered the Agency for Healthcare Research and Quality (AHRQ) National Guidelines Clearinghouse and included both European guidelines and American guidelines. The participants were also asked whether they had received formal training in EB M, such as EU-ebm or CEBM, and if they considered themselves capable of understanding, criticizing, and interpreting statistical outcomes in journals.

Most questions consisted of a five-item Likert scale, which was chosen because each item is of equal value, so the respondents were scored rather than the items. The Likert scale was also likely to yield highly reliable answers and is easy to read and complete [12]. Some questions, for example about formal training in EB M and the ability to understand, criticize, and interpret statistical outcomes, were asked with a choice of Likert scale answers to enable the neurosurgeons to “rate” their training or ability to understand outcomes. The remaining questions had binary answers or were choices between statements. Participation was voluntary and completely anonymous, and the purpose of the survey was explained to the participants.

Statistical Analyses

IBM SPSS version 22 (Armonk, NY, USA) was used for the statistical analyses. For the continuous data, Student t tests were used, whereas chi-square tests were used to analyze categorical data. Some values, for example the number of years as a neurosurgeon, were categorized before being statistically examined. Comparisons were made between different groups.

| Level of evidence | Studies |
|-------------------|---------|
| I                 | (1) Randomized controlled trial, (2) meta-analysis of randomized controlled trials with homogeneous results |
| II                | (1) Prospective comparative study (therapeutic), (2) meta-analysis of level II studies or level I studies with inconsistent results |
| III               | (1) Retrospective cohort study, (2) case-control study, (3) meta-analysis of level III studies |
| IV                | (1) Case series |
| V                 | (1) Case report, (2) expert opinion, (3) personal observation |

Table 1. Levels of evidence in neurosurgery.
of neurosurgeons. Multiple groups were formed based on the answers to the questions asked and their opinions on different aspects, and consisted of respondents responding with a positive answer ("strongly agree," "agree," or "yes"), a negative answer ("strongly disagree," "disagree," or "no"), or an indecisive answer ("indifferent") to particular questions. Afterwards, comparisons were made between the answers and opinions of certain groups for different aspects of neurosurgery. Values are presented as a mean ±95% confidence interval (CI).

Results

The response rate was 6.78% (177 respondents) of the 2552 EANS members surveyed. All completed surveys contained complete data and had no partial or missing responses. Four respondents were excluded: three were still residents and one response was sent twice. A final total of 173 completed surveys (6.78%) were analyzed.

Respondent Statistics

Table 2 shows the demographics of the respondents. Their years of experience varied. Most respondents (98.3%, 170/173) were specialized in one or more subspecialties. Of these, 85.9% (146/170) were specialized in two or more subspecialties, with a mean of 3.2 per person (95% CI 2.97-3.43). A total of 57.2% (99/173) of the respondents had one or more academic qualifications, such as a professorship or a PhD. The majority of the respondents (79.2%, 137/173) worked in one of 29 European countries, mostly Germany (10.4%, 18/173), the Netherlands (7.5%, 13/173), Greece (6.4%, 11/173), or the United Kingdom (5.8%, 10/173).

| Demographics                                      | n (%)       |
|---------------------------------------------------|-------------|
| Years working as a neurosurgeon                   |             |
| 1-5                                               | 30 (17.3)   |
| 5-10                                              | 46 (26.6)   |
| 10-15                                             | 38 (22.0)   |
| 15-20                                             | 13 (7.5)    |
| 20-25                                             | 13 (7.5)    |
| 25-30                                             | 16 (9.3)    |
| >30                                               | 17 (9.8)    |
| Academic qualifications                           |             |
| Yes\(^a\)                                         | 99 (57.2)   |
| Professor                                         | 28 (23.0)   |
| PhD                                               | 67 (54.9)   |
| MSPH                                              | 2 (1.6)     |
| MPH                                               | 5 (4.1)     |
| Other                                             | 20 (16.4)   |
| Subspecialty                                      |             |
| Yes\(^c\)                                         | 170 (98.3)  |
| Neurocritical care                                | 62 (11.7)   |
| Cerebrovascular neurosurgery                      | 70 (13.2)   |
| Neuroendovascular surgery                         | 14 (2.6)    |
| Spinal neurosurgery                               | 121 (22.9)  |
| Neurosurgical oncology                            | 125 (23.6)  |
| Pediatric neurosurgery                            | 57 (10.8)   |
| Peripheral nerve neurosurgery                     | 35 (6.6)    |
| Stereotactic and functional neurosurgery          | 30 (5.7)    |
| Other                                             | 15 (2.8)    |

\(^a\)PhD: Doctor of Philosophy; MPH: Master of Public Health; MSPH: Master of Science in Public Health.

\(^b\)28.6% of the neurosurgeons who answered “yes” had more than one academic qualification, with a mean of 1.2 per person (95% CI 1.11-1.29).

\(^c\)85.9% of the neurosurgeons who answered “yes” had more than one subspecialty, with a mean of 3.2 per person (95% CI 2.97-3.43).
The remaining 36 respondents (20.8%, 36/173) worked in one of 18 non-European countries, particularly in countries in the Middle East (11.6%, 20/173), such as Saudi Arabia (2.9%, 5/173), Pakistan (2.3%, 4/173), and Iraq (1.7%, 3/173). The remaining respondents came mainly from Mexico (1.7%, 3/173), India (1.7%, 3/173), and the United States (1.2%, 2/173).

Evaluation Outcomes

Table 3 shows the opinions of the respondents regarding the levels of evidence and the use of EBM in clinical practice. Of the 173 respondents, 84 (48.6%) considered level I or level I and level II evidence to be of high quality. Figure 1 shows the levels of evidence used by neurosurgeons in clinical practice; most respondents implemented all levels of evidence into their clinical practice. The results of randomized controlled trials (RCTs) with inconsistent, but promising, results were used by fewer than half of the respondents (45.7%, 79/173; Tables 4 and 5).

| Levels of evidence | Considered to be of high quality and usable in clinical practice, n (%) |
|--------------------|---------------------------------------------------------------|
| None               | 3 (1.7)                                                        |
| Level I            | 15 (8.7)                                                       |
| Level I and level II | 69 (39.9)                                                     |
| Level I, level II, and level III | 53 (30.6)         |
| Level I, level II, level III, and level IV | 2 (1.2)          |
| All levels (Level I-V) | 31 (17.9)                                                   |

Every participant indicated the guidelines they used most often, to a maximum of three guidelines (Table 6). The level of evidence generated by the research underpinning each guideline is shown. Guidelines considering the surgical management of traumatic brain injury were most commonly used (39.3%, 68/173), followed by those for severe traumatic brain injury (38.2%, 66/173) and subarachnoid hemorrhage (38.2%, 66/173). Table 6 also shows the number of neurosurgeons using the guideline who subspecialized in the corresponding area of neurosurgery. The numbers of neurosurgeons specializing in the areas corresponding to the three most-used guidelines did not comprise a large percentage of the total number of neurosurgeons using these guidelines (48.5%, 48.5%, and 78.8% of neurosurgeons specializing in the surgical management of traumatic brain injury, severe traumatic brain injury, and subarachnoid hemorrhage, respectively). This may be because these three areas are all critical conditions that require immediate care; therefore, it is likely that most neurosurgeons will use these guidelines even if it is not their subspecialty.

Table 3. Levels of evidence considered by neurosurgeons to be of high quality and usable in clinical practice.

Figure 1. Levels of evidence used by neurosurgeons in clinical practice. The results are presented on a five-item Likert scale: (1) strongly agree, (2) agree, (3) indifferent, (4) disagree, or (5) strongly disagree.
Table 4. Studies used by the participants in clinical practice. Scores were given from 1 (strongly disagree) to 5 (strongly agree).

| Level of evidence | Studies | Studies used, mean (95% CI) |
|-------------------|---------|-----------------------------|
| I                 | (1) RCT\textsuperscript{a}, (2) meta-analysis of RCTs with homogeneous results | 3.8 (2.14-5.46) |
| II                | (1) Prospective comparative study (therapeutic) | 3.9 (2.48-5.32) |
| II                | (2) Meta-analysis of level II studies | 3.9 (2.34-5.46) |
| II                | (3) Meta-analysis of level I studies with inconsistent results | 3.3 (1.54-5.06) |
| III               | (1) (Meta-analysis of) retrospective cohort study | 3.8 (2.36-5.24) |
| III               | (2) Case-control study | 3.6 (2.06-5.14) |
| IV                | (1) Case series | 3.7 (2.02-5.38) |
| V                 | (1) Case report, (2) expert opinion, (3) personal observation | 3.5 (1.64-5.36) |

\textsuperscript{a}RCT: randomized controlled trial.

Table 5. Summary of the overall survey results (N=173).

| Survey item                                      | Strongly agree or agree, n (%) | Indifferent, n (%) |
|-------------------------------------------------|--------------------------------|--------------------|
| **Factors important for choosing a treatment**   |                                |                    |
| Clinical experience is an important factor for choosing a treatment | 172 (99.4) | 0 (0.0) |
| Research is an important factor for choosing a treatment | 160 (92.5) | 10 (5.8) |
| Knowledge from patients and carers is an important factor for choosing a treatment | 124 (71.7) | 39 (22.4) |
| Local context and environment are important factors for choosing a treatment | 123 (71.1) | 42 (24.3) |
| **Use of research in clinical practice**        |                                |                    |
| I use prospective cohort studies in clinical practice | 134 (77.5) | 34 (19.7) |
| I use meta-analysis of prospective cohort studies in clinical practice | 130 (75.1) | 35 (20.2) |
| I use (meta-analysis of) retrospective cohort studies in clinical practice | 126 (72.9) | 39 (22.5) |
| I use (meta-analysis of) RCTs\textsuperscript{a} with homogeneous results in clinical practice | 122 (70.5) | 41 (23.7) |
| I use case-control studies in clinical practice | 113 (65.3) | 42 (24.3) |
| I use case series in clinical practice | 111 (64.2) | 47 (27.2) |
| I use case reports, expert opinions, or personal observations in clinical practice | 98 (56.6) | 52 (30.1) |
| I use (meta-analysis of) RCTs with inconsistent, but promising, results in clinical practice | 79 (45.7) | 66 (38.2) |
| **Guidelines and treatment options**             |                                |                    |
| Treatment options I use are based on high-quality evidence | 129 (74.5) | 26 (15.0) |
| The neurosurgeons at my hospital are involved in the process of setting up the neurosurgical guidelines for my hospital | 126 (72.8)\textsuperscript{b} | 3 (1.7)\textsuperscript{c} |
| Guidelines at my hospital are based on high-quality evidence | 102 (59.0) | 49 (28.3) |
| **Training**                                    |                                |                    |
| I can understand, criticize, and interpret statistical outcomes in journals | 87 (80.3) | 19 (11.1) |
| I have received formal training in EBM\textsuperscript{d} | 60 (34.7) | 29 (16.8) |
| Neurosurgery is amenable to evidence | 146 (84.4) | 19 (11.0) |

\textsuperscript{a}RCT: randomized controlled trial.
\textsuperscript{b}Question was answered with “yes.”
\textsuperscript{c}Question was answered with “other.”
\textsuperscript{d}EBM: evidenced-based medicine.
Table 6. Most-used neurosurgical guidelines (N=173).

| Guidelines                                      | Level of evidence in research used to develop guideline [11] | Neurosurgeons using this guideline, n (%) | Neurosurgeons using this guideline subspecialized in this field, n (%) |
|-------------------------------------------------|-------------------------------------------------------------|------------------------------------------|----------------------------------------------------------|
| Head injury                                     | --\(^a\)                                                    | 150 (86.7)                               | --                                                       |
| Surgical management of traumatic brain injury   | Moderate                                                    | 68 (39.3)                                | 33 (49)                                                  |
| Severe traumatic brain injury                   | Moderate                                                    | 66 (38.2)                                | 32 (49)                                                  |
| Pediatric traumatic brain injury                | Moderate                                                    | 9 (5.2)                                  | 7 (44)                                                   |
| Mild traumatic brain injury                     | High/moderate                                               | 7 (4.0)                                  | 4 (44)                                                   |
| Spine                                           | --                                                         | 136 (78.6)                               | --                                                       |
| Lumbar disk herniation                          | All levels                                                 | 38 (22.0)                                | 32 (84)                                                  |
| Cervical spine and spinal cord injury           | Moderate                                                   | 19 (11.0)                                | 19 (100)                                                 |
| Degenerative lumbar spondylolisthesis           | Moderate/low                                                | 17 (9.8)                                 | 15 (88)                                                  |
| Degenerative lumbar stenosis                    | Moderate/low                                                | 13 (7.5)                                 | 10 (77)                                                  |
| Degenerative cervical spine disease             | Moderate                                                   | 11 (6.4)                                 | 11 (100)                                                 |
| Lumbar spine fusion                             | All levels                                                 | 11 (6.4)                                 | 10 (91)                                                   |
| Cervical radiculopathy and degenerative disease | All levels                                                 | 10 (5.8)                                 | 10 (100)                                                  |
| Antibiotic prophylaxis in spine surgery         | All levels                                                 | 9 (5.2)                                  | 7 (78)                                                   |
| Intraoperative spinal monitoring                | High                                                       | 6 (3.5)                                  | 4 (67)                                                   |
| Somatosensory evoked potentials                 | Moderate                                                   | 1 (0.6)                                  | 1 (100)                                                  |
| Vertebral osteomyelitis, diskitis, and epidural abscess | Moderate/low                                               | 1 (0.6)                                  | 1 (100)                                                  |
| Vascular                                        | --                                                         | 96 (55.5)                                | --                                                       |
| Subarachnoid hemorrhage                         | All levels                                                 | 66 (38.2)                                | 52 (79)                                                  |
| Intracerebral hemorrhage                        | High                                                       | 23 (13.3)                                | 19 (83)                                                  |
| Extradural carotid disease                      | High/moderate                                               | 7 (4.0)                                  | 6 (86)                                                   |
| Tumor                                           | --                                                         | 81 (46.8)                                | --                                                       |
| Glioblastoma                                    | Moderate                                                   | 60 (34.7)                                | 52 (87)                                                  |
| Brain metastases                                | High/moderate                                               | 21 (12.1)                                | 18 (86)                                                  |
| Functional                                      | --                                                         | 11 (6.4)                                 | --                                                       |
| Deep brain stimulation                          | High/moderate                                               | 10 (5.8)                                 | 9 (90)                                                   |
| Vagal nerve stimulation                         | Moderate                                                   | 1 (0.2)                                  | 0 (0)                                                    |
| Other                                           | --                                                         | 22 (4.4)                                 | --                                                       |
| Hydrocephalus                                    | Moderate                                                   | 18 (3.6)                                 | 14 (78)                                                  |
| Carpal tunnel syndrome                          | High/moderate                                               | 4 (0.8)                                  | 1 (25)                                                   |

\(^a\)Not applicable.

According to 84.4% of the neurosurgeons (146/173), neurosurgery is amenable to evidence (Table 5); however, nearly half of the respondents (48.6%, 84/173) believed that neurosurgery is less based on evidence than other medical specialties. Despite this, 74.6% of the respondents (129/173) consider their treatments to be based on level I and/or level II evidence. Of those who believed neurosurgery is amenable to evidence, 78.8% (115/146 respondents) considered their treatments to be based on level I and/or level II evidence, whereas significantly fewer (25%, 2/8) of those who did not believe neurosurgery is amenable to evidence considered their research to be based on such high-quality evidence \((P=0.048)\). Of the most-used neurosurgical guidelines (Table 6), only 9.78% (242/2469) were based on level I evidence, whereas 20.43% (545/2668) were based on level II evidence.

Of the 129 respondents who believed their treatments were based on high-quality evidence, 50.4% (65/129) considered level I and/or level II to be high-quality evidence, whereas significantly fewer (39%, 7/18) of the respondents who did not consider their treatments to be based on high-quality evidence considered level I and/or level II to be high quality \((P=0.02)\). Most respondents (72.8%, 126/173) were involved in the process of setting up the neurosurgical guidelines in their hospital. More
than half (59.0%, 102/173) of the respondents considered the
neurosurgical guidelines of their hospital to be based on
high-quality evidence. Of those who were involved in their
establishment, 65.9% (83/126) considered the guidelines of
their hospital to be based on high-quality evidence, compared
with just 43% (20/47) of those who were not involved (P=.02).

Of the 59.0% (102/173) of respondents who considered the
neurosurgical guidelines in their hospital to be based on
high-quality evidence, 84.3% (86/102) considered their own
treatments to be based on level I and/or level II evidence,
whereas 55% (12/22) of the respondents who did not consider
hospital guidelines to be based on high-quality evidence
considered their own treatments to be based on level I and/or
level II evidence (P<.001).

Only 34.7% (60/173) of the respondents said they had received
formal training in EBM. Of those who received formal training,
76% (46/60) considered their own treatments to be based on
level I and/or level II evidence, whereas 85% (71/84) of those
without formal training believed their treatments were based on
this level of evidence (P=.03).

The majority of respondents (80.3%, 139/173) said they could
understand, criticize, and interpret statistical outcomes in
medical research. This response was more common for
respondents who received formal training (93%, 56/60) than
for those without formal training (68%, 57/84; P<.001). There
was no difference between the number of respondents with and
without additional academic qualifications who stated that they
could understand, criticize, and interpret statistical outcomes
(85%, 84/99 and 74%, 55/74, respectively; P=.16).

All participants had the option to add their own comments at
the end of the survey. The most frequent comment was that the
lack of evidence is an important issue in neurosurgery.
Neurosurgeons also said that RCTs are expensive and difficult
to perform, although well-designed prospective comparative
studies could be equally informative and easier to run. They
therefore concluded that dismissing study designs other than
RCTs when developing neurosurgical guidelines is holding back
neurosurgery.

Discussion

This study is unique because it is, to the best of our knowledge,
the first to evaluate the opinion of neurosurgeons in several
countries regarding the use of evidence in neurosurgery. Level
I and level II evidence is considered high quality; however,
despite a worldwide acceptance of this classification, only 48.5% of
the respondents (84/173) considered either level I or levels I
and II to be high quality. Moreover, all levels of evidence seem
to be used by the majority of neurosurgeons. Several
neurosurgeons commented that the lack of evidence is an
important issue in neurosurgery.

Indisputable advancements in neurosurgery have been
traditionally based on technical innovations advocated by
pioneers without rigid assessment in clinical trials; therefore,
changes in clinical practice have frequently been
technology-driven rather than strictly evidence-based [13].
Everyday clinical management in neurosurgery does not,
therefore, always seem to comply with the best available
evidence.

Since 1970, the rate of increase in the publication of guidelines
in all specialties has outpaced neurosurgery [11]; however, in
the past 5 years, the number of guidelines published per year
in neurosurgery has increased at the same rate as all specialties
[11]. The available literature shows that neurosurgery uses a
higher percentage of high-level evidence than some other
specialties, including general plastic surgery [14] and
maxillofacial surgery [15]; however, neurosurgery is still lagging
behind many other specialties, including orthopedics [16],
ophthalmology [17], otolaryngology [18], esthetic surgery [19],
and urology [20]. The situation in other fields resembles that
of neurosurgery; for example, 12.2% of the treatment for atrial
fibrillation is based on level I and II evidence [21], although we
could not find any data on the levels of evidence used in the
treatment of cardiovascular disease as a whole. When comparing
neurosurgery with oncology, we discovered that oncology uses the
AGREE (Appraisal of Guidelines for Research and
Evaluation) rating of guidelines [22-25]. The AGREE domains
(scope and purpose, stakeholder involvement, rigor of
development, clarity of presentation, applicability, and editorial
independence) [26] are not comparable with the levels of
evidence, in which studies are graded by study design.

Of the respondents who participated in this study, 25.4%
(44/173) did not think that, or know whether, the treatment
options they use are based on high-quality evidence. Ducis et
al [11] investigated the quality of the guidelines used in
neurosurgery clinical practice. In neurosurgery, 24.4% of the
guidelines were based mainly on level I recommendations,
whereas for vascular neurosurgery guidelines this percentage
is significantly higher: 51.9%. Some other specialties have
numbers of level I-based recommendations similar to
neurosurgery, including endocrinology [27], infectious diseases
[28], and hepatology [29]. Vascular neurosurgery is the
subspecialty with the highest publication rate in neurosurgery
[5], and vascular neurosurgery guidelines are the third most
commonly used in clinical practice (according to Table 6).
Guidelines relating to traumatic brain injuries are the most used
according to the respondents, but this subspecialty accounted
for just 6.4% of neurosurgery publications between 2009 and
2010 [5]. The level I-based recommendations for traumatic
brain injury guidelines accounted for only 5.6% of all
recommendations [11], significantly less than the level I-based
recommendations for spine guidelines (10.0%) and vascular
guidelines (51.0%), as assessed with a chi-square test (P<.001).
One participant commented that neurosurgery is currently based
more on eminence than on evidence. Eminence refers to a
clinical decision that is made solely by relying on the opinion of
a medical specialist or any prominent health professional
rather than the critical appraisal of the scientific evidence
available [30]. Evidence is an integration of clinical knowledge
and skills with the best critically appraised research available,
as well as patient values and preferences, in order to make a
clinical decision [30]. With the lack of evidence available to
neurosurgeons, neurosurgery seems indeed to be based more
on eminence than evidence in some cases.
Another neurosurgeon commented that the current definition of evidence-based neurosurgery is in dire need of rigorous update and expansion. A common misunderstanding of EBM is that a lack of available evidence means a lack of RCTs [31]. EBM evaluates the quality of evidence, based primarily on the likelihood that the evidence is biased. A powerful RCT is the best standard for evaluating this inherent bias, but it does not follow that only RCTs can be used to justify clinical practice in EBM; rather, EBM requires that we attempt to audit our decisions by obtaining the highest level of evidence ethically or logistically possible [31,32].

The differences in the confidence of neurosurgeons with and without formal training in EBM to adequately interpret the statistical outcomes presented in the literature was striking. Only 35% of the responding neurosurgeons (60/173) had received formal training in EBM and although it seems low, it is similar to that described in orthopedic surgery [33]. The lack of EBM training in neurosurgery has already been noted elsewhere; the University of Western Ontario in London, ON, Canada [34], and the American Accreditation Council for Graduate Medical Education [31] recently incorporated EBM into the curriculum for residency training programs in neurosurgery. Since EBM is based on the implementation of correctly interpreted research results, our findings may represent an argument for the introduction of more formal EBM training in the medical curriculum and supplementary training for neurosurgical departments.

A major strength of this study is the broad representation of the opinions of neurosurgeons worldwide through the involvement of the EANS. EANS has a large number of members all over the world. The membership of EANS is primarily located in Europe, but neurosurgeons from all countries are permitted to join. However, some potential limitations should also be discussed. First, due to the low response rate, selection bias cannot be precluded, which hampers the generalizability of our results. For external email surveys, a response rate between 10% to 25% is usually considered the average [35,36]. The response rate to our survey was a little lower than average, which might be caused by a general lack of interest by neurosurgeons or because they did not recognize the importance of this study. Bias could have been introduced because the survey may have been selectively answered by those who consider EBM important, specifically by those who were trained in EBM, involved in innovation and guidelines, or opinion leaders. Second, the participants of the survey may have chosen to provide socially desirable answers; however, this was counteracted by emphasizing the anonymity of the survey. A third potential issue is that neurosurgery is in the middle of transitioning from rating the guidelines using levels of evidence to rating them with the GRADE guidelines. We choose to use the levels of evidence here because they are currently more widely used by neurosurgeons; however, this could have been confusing for those who have already begun to use the GRADE guidelines.

The transition from using levels of evidence to the GRADE system is an important change in all medical specialties, including neurosurgery. The literature available about the evaluation of evidence in neurosurgery does not include the new system and is, therefore, in need of expansion and updating. The GRADE guidelines offer some major advantages over the levels of evidence, as they enable the rating of evidence in systematic reviews and guidelines and the grading of the strength of recommendations made in guidelines. Moreover, the GRADE system offers a transparent and structured process for developing and presenting summaries of evidence in systematic reviews and guidelines in health care, and for carrying out the steps involved in developing recommendations [6].

There are major gaps between the current definition of high-quality evidence (level I and level II) and neurosurgeons’ opinions of evidence. Neurosurgeons are willing to base their clinical decisions on more than just RCTs, relying on lower-quality evidence. The transition to the GRADE system is one way to overcome this issue because these guidelines are outcome-centric and do not rate each study as a single unit. In the GRADE approach, RCTs are initially considered to be high-quality evidence and observational studies are initially considered low-quality evidence supporting estimates of intervention effects. Five factors may lead the ratings to be decreased, whereas three other factors may lead to an increased rating. Ultimately, the quality of evidence for each outcome falls into one of four categories, from high to very low [6].

EBM is important when choosing between treatments for patients; however, shared decision making (SDM) was also developed alongside the introduction of EBM. According to 71.7% (124/173) of the respondents of this study, knowledge gained from patients and carers was an important factor in the selection of a treatment, whereas 22.5% of the respondents (39/173) were indifferent and 5.8% (10/173) did not believe that the knowledge of patients and carers was an important factor when choosing a treatment. Evidence from trials has shown that engaged patients consume less health care resources [37,38]; furthermore, when doctors are too focused on EBM, preference misdiagnoses (also known as silent misdiagnoses) can be made, causing the patient to receive an unwanted treatment [39]. EBM is important but has to be combined with SDM to give patients the right treatment. Learning to combine these two sides of medicine could be an important development in all specialties, leading to the optimization of health care for patients.

Understanding EBM is key to using it correctly in practice. This study shows that relatively few neurosurgeons have received formal training in EBM; thus, more training in EBM, both in the medical curriculum for residents and at neurosurgical departments, would enable neurosurgeons to improve their abilities to better facilitate the implementation of statistical results into clinical practice. It would be interesting to perform this research on a larger scale, including a wider multinational sample in the future.

According to the respondents, neurosurgery is less commonly based on high-quality evidence than other medical specialties. The results of the survey suggest that providing more formal training in EBM is desirable, enabling neurosurgeons to better understand, criticize, and interpret the statistical outcomes presented in journals.
Acknowledgments

We would like to give our special thanks to Professor JA Grotenhuis for supporting the distribution of the Web-based survey by the EANS. We also express our gratitude to Radboud in’to Languages for performing the English language editing of this manuscript.

Conflicts of Interest

None declared.

Multimedia Appendix 1

"Evidence in Neurosurgery" survey.

References

1. Haines S, Walters B. Evidence-Based Neurosurgery: An Introduction. New York: Thieme Medical Publishers; 2006.
2. Rycroft-Malone J, Seers K, Titchen A, Harvey G, Kitson A, McCormack B. What counts as evidence in evidence-based practice? J Adv Nurs 2004 Jul;47(1):81-90. [doi: 10.1111/j.1365-2648.2004.03068.x] [Medline: 15186471]
3. Carnwell R. Essential differences between research and evidence-based practice. Nurse Researcher 2001 Jan;8(2):55-68. [doi: 10.7748/nr2001.01.8.2.55.e6150]
4. Goodman K. Ethics and Evidence-Based Medicine: Fallibility and Responsibility in Clinical Science. Cambridge: Cambridge University Press; 2002.
5. Yarascavitch BA, Chuback JE, Almenawer SA, Reddy K, Bhandari M. Levels of evidence in the neurosurgical literature: more tribulations than trials. Neurosurgery 2012 Dec;71(6):1131-1137. [doi: 10.1227/NEU.0b013e318271be99] [Medline: 22986592]
6. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011 Apr;64(4):383-394. [doi: 10.1016/j.jclinepi.2010.04.026] [Medline: 21195583]
7. Rutka JT. Editorial. Classes of evidence in neurosurgery. J Neurosurg 2017 Jun;126(6):1747-1748. [doi: 10.3171/2016.4.JNS161067] [Medline: 2736246]
8. Phillips B, Ball C, Sackett D, Badenoch D, Straus S, Haynes B. Centre for Evidence-based Medicine. 2009. Oxford Centre for Evidence-based Medicine-levels of evidence (March 2009) URL: https://tinyurl.com/y9vtoj38 [accessed 2017-12-03] [WebCite Cache ID 6vQ1GXklP]
9. Weber C, Jakola AS, Gulati S, Nygaard OP, Solheim O. Evidence-based clinical management and utilization of new technology in European neurosurgery. Acta Neurochir (Wien) 2013 Apr;155(4):747-754. [doi: 10.1007/s00701-013-1640-1] [Medline: 23440373]
10. Loiselle F, Mahabir RC, Harrop AR. Levels of evidence in plastic surgery research over 20 years. Plast Reconstr Surg 2008 Apr;121(4):207e-211e. [doi: 10.1097/01.prs.0000304600.23129.d3] [Medline: 18349600]
11. Lau SL, Samman N. Levels of evidence and journal impact factor in oral and maxillofacial surgery. Int J Oral Maxillofac Surg 2007 Jan;36(1):1-5. [doi: 10.1016/j.iomj.2006.10.008] [Medline: 17129707]
12. Obrenskey WT, Pappas N, Attallah-Wasif E, Tornetta P, Bhandari M. Level of evidence in orthopaedic journals. J Bone Joint Surg Am 2005 Dec;87(12):2632-2638. [doi: 10.2106/JBJS.E.00370] [Medline: 16322612]
13. Lai TY, Leung GM, Wong VW, Lam RF, Cheng A, Lam DS. How evidence-based are publications in clinical ophthalmic journals? Invest Ophthalmol Vis Sci 2006 May;47(5):1831-1838. [doi: 10.1167/iovs.05-0915] [Medline: 16638988]
14. Wasserman JM, Wynn R, Bash TS, Rosenfeld RM. Levels of evidence in otorhanylogy journals. Otolaryngol Head Neck Surg 2006 May;134(5):717-723. [doi: 10.1016/jotohns.2005.11.049] [Medline: 16647522]
15. Yarascavitch BA, Chuback JE, Almenawer SA, Reddy K, Bhandari M. Evidence in the aesthetic surgical literature over the past decade: how far have we come? Plast Reconstr Surg 2012 Jan;129(1):126e-134e. [doi: 10.1097/PRS.0b013e31823626be] [Medline: 22186527]

http://www.i-jmr.org/2018/2/e16/
20. Borawski KM, Norris RD, Fesperman SF, Vieweg J, Preminger GM, Dahm P. Levels of evidence in the urological literature. J Urol 2007 Oct;178(4 Pt 1):1429-1433. [doi: 10.1016/j.juro.2007.05.150] [Medline: 17706710]

21. Barnett AS, Lewis WR, Fieldi ME, Fonarow GC, Gersh BJ, Page RL, et al. Quality of evidence underlying the American Heart Association/American College of Cardiology/Heart Rhythm Society Guidelines on the management of atrial fibrillation. JAMA Cardiol 2017 Mar 01;2(3):319-323. [doi: 10.1001/jamacardio.2016.4936] [Medline: 28002833]

22. Lei X, Liu F, Luo S, Sun Y, Zhu L, Su F, et al. Evaluation of guidelines regarding surgical treatment of breast cancer using the AGREE Instrument: a systematic review. BMJ Open 2017 Nov 14;7(11):e014883 [FREE Full text] [doi: 10.1136/bmjopen-2016-014883] [Medline: 29138191]

23. Irani S, Rashidian A, Youssefi-Nooraie R, Soltani A. Evaluating clinical practice guidelines developed for the management of thyroid nodules and thyroid cancers and assessing the reliability and validity of the AGREE instrument. J Eval Clin Pract 2011 Aug;17(4):729-736. [doi: 10.1111/j.1365-2753.2010.01561.x] [Medline: 21223456]

24. Chen Y, Wang Y, Li W, Chen L, Xu C, Lu T, et al. Critical evaluation of the quality and recommendations of clinical practice guidelines for nasopharyngeal carcinoma. J Natl Compr Canc Netw 2017 Dec;15(3):336-344. [Medline: 28270534]

25. Klaver CE, Groenen H, Morton DG, Laurberg S, Bemelman WA, Tanis PJ, et al. Recommendations and consensus on the treatment of peritoneal metastases of colorectal origin: a systematic review of national and international guidelines. Colorectal Dis 2017 Mar;19(3):224-236. [doi: 10.1111/codi.13593] [Medline: 28008728]

26. Brouwers MC, Kho ME, Brownman GP, Burgers JS, Cluzeau F, Feder G, AGREE Next Steps Consortium. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010 Dec 14;182(18):E839-E842 [FREE Full text] [doi: 10.1503/cmaj.090449] [Medline: 20603348]

27. Hazlehurst JM, Armstrong MJ, Sherlock M, Rowe IA, O'Reilly MW, Franklin JA, et al. A comparative quality assessment of evidence-based clinical guidelines in endocrinology. Clin Endocrinol (Oxf) 2013 Feb;78(2):183-190. [doi: 10.1111/cen.12259] [Medline: 22624723]

28. Lee DH, Viellemeyer O. Analysis of overall level of evidence behind Infectious Diseases Society of America practice guidelines. Arch Intern Med 2011 Jan 10;171(1):18-22. [doi: 10.1001/archinternmed.2010.482] [Medline: 21220656]

29. Rowe IA, Parker R, Armstrong MJ, King AL, Houlihan DD, Mutimer D. Assessment of the quality of evidence underlying national guidelines in liver disease. Am J Gastroenterol 2012 Sep;107(9):1276-1282. [doi: 10.1038/aajg.2012.71] [Medline: 22951868]

30. Le HP. Students 4 Best Evidence. 2016 Jan 12. Evidence-based medicine vs evidence-based medicine URL: http://www.students4bestevidence.net/eminence-based-medicine-vs-evidence-based-medicine/ [accessed 2017-12-03] [WebCite Cache ID 6vQ1SMuhb]

31. Bandopadhyay P, Goldschlager T, Rosenfeld JV. The role of evidence-based medicine in neurosurgery. J Clin Neurosci 2008 Apr;15(4):373-378. [doi: 10.1016/j.jocn.2007.08.014] [Medline: 18249115]

32. Haines SJ. Evidence-based neurosurgery. Neurosurgery 2003 Jan;52(1):36-47; discussion 47. [Medline: 12493099]

33. Kumar M, Gopalakrishna C, Swaminath PV, Mysore SS. Evidence-based surgery--evidence from survey and citation analysis in orthopaedic surgery. Ann R Coll Surg Engl 2011 Mar;93(2):133-138 [FREE Full text] [doi: 10.1308/003588411X1285163910787] [Medline: 21073824]

34. Burneo JG, Jenkins ME, UWO Evidence-Based Neurology Group. Teaching evidence-based clinical practice to neurology and neurosurgery residents. Clin Neurol Neurosurg 2007 Jun;109(5):418-421. [doi: 10.1016/j.clineuro.2007.03.001] [Medline: 17418941]

35. Fryrear A. SurveyGizmo. 2015. 3 Ways to improve your survey response rates URL: https://www.surveygizmo.com/survey-blog/survey-response-rates/ [accessed 2017-12-03] [WebCite Cache ID 6vQ1fU41n]

36. Fineham JE. Response rates and responsibilities for surveys, standards, and the Journal. Am J Pharm Educ 2008 Apr 15;72(2):43 [FREE Full text] [Medline: 18483608]

37. Stacey D, Légaré F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev 2011;4:CD001431. [doi: 10.1002/14651858.CD001431.pub2] [Medline: 28402085]

38. Wennberg DE, Marr A, Lang L, O'Malley S, Bennett G. A randomized trial of a telephone care-management strategy. N Engl J Med 2010 Sep 23;363(13):1245-1255. [doi: 10.1056/NEJMsa0902321] [Medline: 20860506]

39. Mulley AG, Trimble C, Elwyn G. Stop the silent misdiagnosis: patients' preferences matter. BMJ 2012 Nov 8;345:e6572. [Medline: 23137819]

**Abbreviations**

AGREE: Appraisal of Guidelines for Research and Evaluation

AHRQ: Agency for Healthcare Research and Quality

EANS: European Association of Neurosurgical Societies

EBM: evidence-based medicine

GRADE: Grading of Recommendations Assessment, Development, and Evaluation
